XML 87 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Expenses - Summary of expenses (Detail) - AUD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Loss before income tax includes the following specific      
Employee benefits expense- salaries & wages and staff benefits $ 1,664 $ 336 $ 861
Employee benefits expense- superannuation 25 26 43
Employee benefits expense- share based payments 365 8 32
Amortisation 1,953 1,265 1,084
Net foreign exchange loss 0 430
Minimum lease payments 73 93 108
Defined contribution superannuation expense 138 138 140
Chinese With-Holding Tax incurred on license transaction 0 931
Chinese Value Added Tax incurred on license transaction 0 538
Total other expenses 0 1,469
Total research & development (excluding amortisation) 18,299 13,276 8,410
Total research & development 20,252 14,541 9,494
Employee benefits expense G&A      
- salaries & wages and staff benefits 1,674 1,011 1,078
- superannuation 129 112 96
- share based payments 1,310 552 230
Total employee benefits expense G&A 3,113 1,675 1,404
EVT-801 program costs [member]      
Loss before income tax includes the following specific      
Research and development 2,520 1,073
Cantrixil program costs [member]      
Loss before income tax includes the following specific      
Research and development 12 429 1,673
Paxalisib program costs [member]      
Loss before income tax includes the following specific      
Research and development 13,713 11,404 5,801
Paxalisib licensing agreement [member]      
Loss before income tax includes the following specific      
Amortisation 1,084 1,084 $ 1,084
Evotec Licensing Agreement [member]      
Loss before income tax includes the following specific      
Amortisation $ 869 $ 181